Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Maolac Ltd. is managing 1 pending office action in the Biotechnology & Pharmaceuticals technology area. This active application is assigned to a distinct examiner and a distinct art unit, reflecting a localized prosecution strategy. The company's current engagement with the patent office is limited to this technical intersection, which requires a specialized understanding of the relevant biological standards.
The busiest examiner, LEE, JIA-HAI, is responsible for the 1 pending office action. As there are no other examiners involved in the portfolio at this time, the prosecution outcomes are tied directly to the decisions of this individual. Understanding the examiner's past behavior in the Biotechnology & Pharmaceuticals field is essential for anticipating the next steps in this matter and ensuring that the claims meet the specific requirements of the unit.
With the distinct art unit involved, the administrative complexity of the portfolio remains low. There is no need to coordinate between different units or adapt to multiple sets of internal guidelines. The active office action serves as the sole focal point for the company's current intellectual property development efforts, allowing for a streamlined approach to patent acquisition.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Double-patenting + other | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| LEE, JIA-HAI | 1 | 49.0% | +46.9% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17767056 | A composition for boosting the immune system | LEE, JIA-HAI | 35d overdue |
| Art Unit | Apps |
|---|---|
| 1658 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 17767056 | A composition for boosting the immune system | LEE, JIA-HAI | 1658 | §103§112DP | Non-Final OA | 35d overdue | Pending | Apr 07, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialMaolac Ltd. has 1 pending office actions as of November 2026, spread across 1 art units and 1 examiners.
Jia-Hai Lee has the most, with 1 of Maolac Ltd.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.